Entropy Technologies LP purchased a new stake in shares of Haleon plc (NYSE:HLN - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 79,801 shares of the company's stock, valued at approximately $761,000.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Fortitude Family Office LLC bought a new stake in Haleon during the 3rd quarter valued at $28,000. Versant Capital Management Inc grew its position in shares of Haleon by 2,029.1% in the fourth quarter. Versant Capital Management Inc now owns 3,513 shares of the company's stock valued at $34,000 after purchasing an additional 3,348 shares in the last quarter. Geneos Wealth Management Inc. bought a new stake in shares of Haleon during the 4th quarter valued at $35,000. Toronto Dominion Bank boosted its stake in Haleon by 3,470.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company's stock worth $38,000 after purchasing an additional 3,470 shares during the period. Finally, Spire Wealth Management purchased a new position in Haleon during the 4th quarter valued at about $39,000. Institutional investors own 6.67% of the company's stock.
A number of equities research analysts have recently issued reports on HLN shares. Sanford C. Bernstein downgraded shares of Haleon from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 8th. Morgan Stanley cut shares of Haleon from an "overweight" rating to an "equal weight" rating in a research note on Friday, January 10th. Three equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $10.95.
Read Our Latest Analysis on HLN
Shares of HLN opened at $9.85 on Wednesday. Haleon plc has a 12-month low of $7.89 and a 12-month high of $10.80. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The company has a market cap of $44.57 billion, a PE ratio of 28.96, a price-to-earnings-growth ratio of 2.70 and a beta of 0.28. The stock has a 50-day moving average price of $9.53 and a 200-day moving average price of $9.79.
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.